However, a selected pre-2010 systematic review and meta-analysis of a case-control study revealed that the oral CP does not aggravate BC risk but rather its use for more than 5 years or before a first full-term pregnancy can modify BC development [49]. This evidence concerns the gene CP and breast cancer.